source
- CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trialCG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
- Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to add blood-cancer assetsEli Lilly announced it will acquire privately held Calytrix Bio in a deal valued at up to $1.5 billion in cash. The acquisition is Lilly’s 14th buyout this year and adds a blood-cancer program to…